Eton Pharmaceuticals (NASDAQ:ETON) Given New $26.00 Price Target at Craig Hallum

Eton Pharmaceuticals (NASDAQ:ETON - Free Report) had its price target hoisted by Craig Hallum from $23.00 to $26.00 in a research report report published on Wednesday morning,Benzinga reports. Craig Hallum currently has a buy rating on the stock.

Other equities analysts have also recently issued reports about the company. B. Riley reissued a "buy" rating and issued a $24.00 target price (up from $21.00) on shares of Eton Pharmaceuticals in a report on Wednesday. HC Wainwright reissued a "buy" rating and set a $33.00 price objective on shares of Eton Pharmaceuticals in a report on Wednesday.

Eton Pharmaceuticals Trading Down 3.8 %

ETON traded down $0.56 during trading on Wednesday, hitting $14.22. The stock had a trading volume of 223,652 shares, compared to its average volume of 159,818. The firm has a market cap of $370.45 million, a PE ratio of -64.64 and a beta of 1.37. The company has a 50 day simple moving average of $15.58 and a 200-day simple moving average of $11.63. Eton Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $18.41.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.02). Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. The business had revenue of $11.65 million for the quarter, compared to the consensus estimate of $10.53 million. As a group, sell-side analysts anticipate that Eton Pharmaceuticals will post -0.14 earnings per share for the current fiscal year.

Remove Ads

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Jefferies Financial Group Inc. bought a new position in shares of Eton Pharmaceuticals during the 4th quarter worth approximately $133,000. Two Sigma Advisers LP bought a new position in Eton Pharmaceuticals in the fourth quarter valued at $662,000. Two Sigma Investments LP acquired a new stake in Eton Pharmaceuticals in the 4th quarter valued at $1,498,000. Point72 Asia Singapore Pte. Ltd. lifted its position in Eton Pharmaceuticals by 18.3% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 10,561 shares of the company's stock worth $141,000 after buying an additional 1,634 shares in the last quarter. Finally, Parkman Healthcare Partners LLC boosted its stake in shares of Eton Pharmaceuticals by 6.4% during the 4th quarter. Parkman Healthcare Partners LLC now owns 276,890 shares of the company's stock worth $3,688,000 after buying an additional 16,664 shares during the last quarter. Institutional investors and hedge funds own 27.86% of the company's stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.